This article is
- freely available
Targeting HTLV-1 Activation of NFκB in Mouse Models and ATLL Patients
Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Campus Box 8069, 660 S. Euclid Ave., St. Louis, MO 63110, USA
* Author to whom correspondence should be addressed.
Received: 27 April 2011; in revised form: 7 June 2011 / Accepted: 9 June 2011 / Published: 21 June 2011
Abstract: Of the millions of HTLV-1 infected carriers worldwide, 3–5% will develop an aggressive T-cell neoplasm that is highly refractory to conventional therapy. The virus carries the Tax oncogene which constitutively activates the NFκB pathway. This co-option of signaling through NFκB provides for the HTLV-1 infected cell an escape from cell cycle arrest and apoptosis, a steady source of growth factors, and a mechanism by which the virus can activate its own target cell. Therapies that target the NFκB pathway sensitize adult T-cell leukemia/lymphoma (ATLL) cells to apoptosis. A focus on translational interrogation of NFκB inhibitors in animal models and ATLL patients is needed to advance NFκB-targeted ATLL therapies to the bedside.
Keywords: HTLV-1; tax; NFκB; mouse models; ATLL therapy
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Rauch, D.A.; Ratner, L. Targeting HTLV-1 Activation of NFκB in Mouse Models and ATLL Patients. Viruses 2011, 3, 886-900.
Rauch DA, Ratner L. Targeting HTLV-1 Activation of NFκB in Mouse Models and ATLL Patients. Viruses. 2011; 3(6):886-900.
Rauch, Daniel A.; Ratner, Lee. 2011. "Targeting HTLV-1 Activation of NFκB in Mouse Models and ATLL Patients." Viruses 3, no. 6: 886-900.